Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nucleic Acid Therapeutics CDMO Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Gene Therapy, RNA-based Therapies)
5.2.2. By Service (Process Development & Optimization, Manufacturing Services, Analytical and Quality Control Services, others)
5.2.3. By Application (Oncology, Genetic Disorders, Infectious Diseases, others)
5.2.4. By Region
5.2.5. By Company (2023)
5.3. Market Map

6. Asia Pacific Nucleic Acid Therapeutics CDMO Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Service
6.2.3. By Application
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Nucleic Acid Therapeutics CDMO Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Service
6.3.1.2.3. By Application
6.3.2. India Nucleic Acid Therapeutics CDMO Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Service
6.3.2.2.3. By Application
6.3.3. Australia Nucleic Acid Therapeutics CDMO Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Service
6.3.3.2.3. By Application
6.3.4. Japan Nucleic Acid Therapeutics CDMO Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Service
6.3.4.2.3. By Application
6.3.5. South Korea Nucleic Acid Therapeutics CDMO Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Service
6.3.5.2.3. By Application

7. Europe Nucleic Acid Therapeutics CDMO Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Service
7.2.3. By Application
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Nucleic Acid Therapeutics CDMO Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Service
7.3.1.2.3. By Application
7.3.2. Germany Nucleic Acid Therapeutics CDMO Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Service
7.3.2.2.3. By Application
7.3.3. Spain Nucleic Acid Therapeutics CDMO Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Service
7.3.3.2.3. By Application
7.3.4. Italy Nucleic Acid Therapeutics CDMO Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Service
7.3.4.2.3. By Application
7.3.5. United Kingdom Nucleic Acid Therapeutics CDMO Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Service
7.3.5.2.3. By Application

8. North America Nucleic Acid Therapeutics CDMO Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Service
8.2.3. By Application
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Nucleic Acid Therapeutics CDMO Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Service
8.3.1.2.3. By Application
8.3.2. Mexico Nucleic Acid Therapeutics CDMO Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Service
8.3.2.2.3. By Application
8.3.3. Canada Nucleic Acid Therapeutics CDMO Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Service
8.3.3.2.3. By Application

9. South America Nucleic Acid Therapeutics CDMO Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Service
9.2.3. By Application
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Nucleic Acid Therapeutics CDMO Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Service
9.3.1.2.3. By Application
9.3.2. Argentina Nucleic Acid Therapeutics CDMO Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Service
9.3.2.2.3. By Application
9.3.3. Colombia Nucleic Acid Therapeutics CDMO Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Service
9.3.3.2.3. By Application
10. Middle East and Africa Nucleic Acid Therapeutics CDMO Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Service
10.2.3. By Application
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Nucleic Acid Therapeutics CDMO Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Service
10.3.1.2.3. By Application
10.3.2. Saudi Arabia Nucleic Acid Therapeutics CDMO Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Service
10.3.2.2.3. By Application
10.3.3. UAE Nucleic Acid Therapeutics CDMO Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Service
10.3.3.2.3. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Nucleic Acid Therapeutics CDMO Market: SWOT Analysis

14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape
16.1. Catalent Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Thermo Fisher Scientific
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3. Lonza Group AG
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4. FUJIFILM Diosynth Biotechnologies
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5. Cognate BioServices
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6. Eurofins Genomics
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7. Sirion Biotech
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8. Oxford Biomedica
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. Danaher Corp. (Aldevron)
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer